Home
About Us
Duoribio
Corporate Philosophy
Development History
Core Advantages
Core Products
Lanreotide Acetate
Tirzepatide
Semaglutide
Retatrutide
Pegcetacoplan
Albuvirtide
CDMO Service
Development Phase
Technology Transfer
Process Validation
Registration Declaration
Join Us
Talent Concept
Recruitment Information
News Center
Company News
Technical Disclosure
Contact Us
中文
Core Products
Home
>
Core Products
Lanreotide Acetate
US FDA Registration No.: 041446
Viwe More
Tirzepatide
US FDA Registration No.: 043257
Viwe More
Semaglutide
US FDA Registration No.: 043251
Viwe More
Retatrutide
Three-target GLP-1R/GCGR/GIPR
Viwe More
Pegcetacoplan
Viwe More
Albuvirtide
The world's first long-acting HIV fusion inhibitor. Commercial supply has been achieved.
Viwe More